LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes

被引:34
|
作者
Cannon, Megan V. [1 ]
Sillje, Herman H. W. [1 ]
Sijbesma, Jurgen W. A. [2 ]
Khan, Mohsin A. F. [1 ]
Steffensen, Knut R. [3 ]
van Gilst, Wiek H. [1 ]
de Boer, Rudolf A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
[3] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, Stockholm, Sweden
关键词
Diabetic cardiomyopathy; Left ventricular hypertrophy; LiverX receptor; Natriuretic peptides; LIVER X RECEPTORS; ATRIAL-NATRIURETIC-PEPTIDE; INSULIN-RESISTANCE; DB/DB MICE; AGONIST T0901317; HEART-FAILURE; INHIBITION; CARDIOMYOPATHY; DYSFUNCTION; ACTIVATION;
D O I
10.1007/s00125-015-3827-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Diabetic cardiomyopathy is a myocardial disease triggered by impaired insulin signalling, increased fatty acid uptake and diminished glucose utilisation. Liver X receptors (LXRs) are key transcriptional regulators of metabolic homeostasis. However, their effect in the diabetic heart is largely unknown. Methods We cloned murine Lxr alpha (also known as Nr1h3) behind the a-myosin heavy chain (alpha Mhc; also known as Myh6) promoter to create transgenic (Lxr alpha-Tg) mice and transgene-negative littermates (wild-type [WT]). A mouse model of type 2 diabetes was induced by a high-fat diet (HFD, 60% energy from fat) over 16 weeks and compared with a low-fat diet (10% energy from fat). A mouse model of type 1 diabetes was induced via streptozotocin injection over 12 weeks. Results HFD manifested comparable increases in body weight, plasma triacylglycerol and insulin resistance per OGTT in Lxr alpha-Tg and WT mice. HFD significantly increased left ventricular weight by 21% in WT hearts, but only by 5% in Lxr alpha-Tg. To elucidate metabolic effects in the heart, microPET (positron emission tomography) imaging revealed that cardiac glucose uptake was increased by 1.4-fold in WT mice on an HFD, but further augmented by 1.7-fold in Lxr alpha-Tg hearts, in part through 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and restoration of glucose transporter 4 (GLUT4). By contrast, streptozotocin-induced ablation of insulin signalling diminished cardiac glucose uptake levels and caused cardiac dysfunction, indicating that insulin may be important in Lxr alpha-mediated glucose uptake. Chromatin immunoprecipitation assays identified natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), as potential direct targets of cardiac Lxr alpha overexpression. Conclusions/interpretation Cardiac-specific Lxr alpha overexpression ameliorates the progression of HFD-induced left ventricular hypertrophy in association with increased glucose reliance and natriuretic peptide signalling during the early phase of diabetic cardiomyopathy. These findings implicate a potential protective role for LXR in targeting metabolic disturbances underlying diabetes.
引用
收藏
页码:634 / 643
页数:10
相关论文
共 50 条
  • [1] LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes
    Megan V. Cannon
    Herman H. W. Silljé
    Jürgen W. A. Sijbesma
    Mohsin A. F. Khan
    Knut R. Steffensen
    Wiek H. van Gilst
    Rudolf A. de Boer
    Diabetologia, 2016, 59 : 634 - 643
  • [2] Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes
    List, E. O.
    Palmer, A. J.
    Berryman, D. E.
    Bower, B.
    Kelder, B.
    Kopchick, J. J.
    DIABETOLOGIA, 2009, 52 (08) : 1647 - 1655
  • [3] Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes
    Garg, Amit
    Alam, Maroof
    Bai, Shakuntala
    Dandawate, Monica
    Kumari, Neeta
    Gupta, Sonu
    Agrawal, Usha
    Nagarajan, Perumal
    Reddy, Dumbala Srinivasa
    Kulkarni, Mahesh J.
    Mukhopadhyay, Arnab
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (02) : 253 - 269
  • [4] Targeted Inhibition of Calpain Reduces Myocardial Hypertrophy and Fibrosis in Mouse Models of Type 1 Diabetes
    Li, Ying
    Ma, Jian
    Zhu, Huaqing
    Singh, Manpreet
    Hill, David
    Greer, Peter A.
    Arnold, J. Malcolm
    Abel, E. Dale
    Peng, Tianqing
    DIABETES, 2011, 60 (11) : 2985 - 2994
  • [5] Albumin Deficiency Reduces Hepatic Steatosis and Improves Glucose Metabolism in a Mouse Model of Diet-Induced Obesity
    Abdollahi, Afsoun
    Narayanan, Sanjeev K.
    Frankovich, Alexandra
    Lai, Yen-Chun
    Zhang, Yi
    Henderson, Gregory C.
    NUTRIENTS, 2023, 15 (09)
  • [6] Longitudinal monitoring of cardiac dysfunction with MRI in a mouse model of obesity and type 2 diabetes
    Inès Abdesselam
    Thomas Troalen
    Pauline Pepino
    Anne Dutour
    Frank Kober
    Monique Bernard
    Journal of Cardiovascular Magnetic Resonance, 16 (Suppl 1)
  • [7] Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes
    Axelsson, Annika S.
    Tubbs, Emily
    Mecham, Brig
    Chacko, Shaji
    Nenonen, Hannah A.
    Tang, Yunzhao
    Fahey, Jed W.
    Derry, Jonathan M. J.
    Wollheim, Claes B.
    Wierup, Nils
    Haymond, Morey W.
    Friend, Stephen H.
    Mulder, Hindrik
    Rosengren, Anders H.
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (394)
  • [8] A mathematical model of obesity-induced type 2 diabetes and efficacy of anti-diabetic weight reducing drug
    Siewe, Nourridine
    Friedman, Avner
    JOURNAL OF THEORETICAL BIOLOGY, 2024, 581
  • [9] Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes
    Patra, Debarun
    Banerjee, Dipanjan
    Ramprasad, Palla
    Roy, Soumyajit
    Pal, Durba
    Dasgupta, Suman
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [10] Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model
    Gutierrez-Cuevas, Jorge
    Sandoval-Rodriguez, Ana
    Christian Monroy-Ramirez, Hugo
    Vazquez-Del Mercado, Monica
    Santos-Garcia, Arturo
    Armendariz-Borunda, Juan
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (05) : 927 - 938